‘s Imfinzi (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for treating adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The treatment regimen comprises Imfinzi plus chemotherapy including carboplatin and paclitaxel, followed by Imfinzi monotherapy. The gold standard of business intelligence.
This approval from the FDA is based on a subgroup analysis from the DUO-E Phase III trial, which focused on MMR status. The randomised, multicentre, double-blind, placebo-controlled study assessed Imfinzi plus platinum-based chemotherapy followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib), against chemotherapy alone. It included 699 patients with newly diagnosed advanced or recurrent epithelial endometrial carcinoma.
Patients in the trial were randomised to receive Imfinzi or a placebo every three weeks, alongside platinum-based chemotherapy. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Results showed that the Imfinzi combination regimen reduced the risk of disease progression or death by 58% in patie.
